Many patients with carcinoma of the breast de-velop osteolytic bone metastases which may be accompanied by hypercalcwmia, and when this work was originally begun very little was known about the mechanisms by means of which tumours may induce resorption of bone. We therefore set ourselves four objectives: (1) To adapt and develop an in vitro bioassay which could be used to measure the osteolytic capacity of human breast tumours.
Many patients with carcinoma of the breast de- velop osteolytic bone metastases which may be accompanied by hypercalcwmia, and when this work was originally begun very little was known about the mechanisms by means of which tumours may induce resorption of bone. We therefore set ourselves four objectives: (1) To adapt and develop an in vitro bioassay which could be used to measure the osteolytic capacity of human breast tumours.
(2) To examine the relationship between the in vitro osteolytic activity of the tumours and the incidence of bone metastases and hypercalcTmia in the patients. (3) To identify some or all of the substances produced by tumour tissue which might be responsible for osteolysis. (4) To examine the action of possible inhibitors of the action or synthesis of any osteolysins identified.
Materials and Methods
Measurement of calcium release: The method finally adopted for the in vitro bioassay of osteolytic activity was based on that of Reynolds (1968) . Two-day-old BALB/C mice were injected intraperitoneally with 0.05 ml of 45CaCl2 solution containing 2 tCi of radioactivity and left for 3 days to allow the 45Ca to become incorporated into the bones. The animals were then lightly anesthetized with ether, dipped into 70 % ethanol and decapitated, the calvaria dissected and maintained in organ culture at 37°C on the surface of stainless steel grids in 60-mm Petri dishes in contact with 5 ml of Biggers' tissue culture medium containing 50% heat-inactivated rabbit serum in an atmosphere of 5 % CO2 in air. After 24 hours the medium was replaced with 5 ml of fresh medium and any test tissues (20-30 mg wet weight) introduced into the culture on a separate grid not in contact with the bone.
Cultures of bones maintained in the absence of other tissues, or in the presence of nonmalignant breast tissue, were used as controls. Both the test and control bones were maintained in culture for a further 65 hours. Each bone was then removed from its grid, placed in a standard scintillation counting vial; 1 ml of 10 N hydrochloric acid was added and left at room temperature for twenty minutes for the bone to dissolve; 1 ml of the culture medium was also transferred to a counting vial and 4 ml of distilled water was added to each 1 ml ofculture medium and each dissolved bone. A scintillation counting fluid (10 ml of INSTAGEL: Packard Instrument Company, Inc), was added to each vial, which was shaken vigorously and the radioactivity counted on a Packard liquid scintillation counter (Model 3375).
Because only one-fifth of the culture medium was counted in each case, whereas the total radioactivity left in each of the bones was measured, the percentage release of radioactivity was calculated from the formula:
Percentage release of 45Ca ct/min of medium sample x 5 00 x 10 (ct/min of medium sample x 5) +ct/min bone sample Ih separate experiments it was demonstrated that less than 0.1 % of the radioactive calcium was absorbed by the tumour or other tissues cocultivated with the bones.
The quantity of radioactivity associated with each bone varied between 100 000 and 200 000 ct/min. Proc. roy. Soc. Med. Volume 70 March 1977 Measurement of simultaneous release of 4"Ca and degradation of organic bone matrix: Two-day-old mice were injected intraperitoneally with 0.05 ml of a solution containing 2 pCi of 45CaC12 and 30 jCi of L-[5-3H]proline. The proline became bound into the organic matrix of the bone. After 2-3 days the calvaria were dissected and cultured as above. As the radioactive counts from 45Ca mask to an unacceptable extent the counts for 3H, the two isotopes were physically separated using a Packard Tricarb sample oxidizer. On oxidation any 3H in the sample is released as steam and retrieved through a cooling system as tritiated water. Nonvolatile 45CaO remained at the site of oxidation. The samples were prepared by taking 1 ml of medium and counting for 45Ca as described previously. In order to count the 3H in the culture medium, 3 ml ofmedium was removed and reduced under vacuum to about 1 ml, and this was then absorbed onto a pressed pellet of cotton wool and oxidized.
The 45Ca and 3H remaining in the bones was measured by placing them in 1 ml of 10 N HCI and heating below boiling point in a sand tray for 2 hours in order to hydrolyse the organic matrix of the bone. The acid was allowed to evaporate but the containers were removed as soon as dryness was achieved to prevent the hydrolysates from charring. Each hydrolysate was then dissolved in 1 ml of distilled water, 0.2 ml of which was counted for 45Ca content directly, while the remaining 0.8 ml was added to the cotton-wool pellet and the 3H converted to 3H20 and counted as 3H in the scintillation counter. With allowance for the volumes of the sample actually counted the percentages of 45Ca and 3H remaining in the cultured bones and released into the medium could be calculated.
Radioimmunoassaysfor Prostaglandins PGA1, PGA2, PGE1, PGE2, PGF1, and PGF2, were donated by Dr J E Pike (Upjohn Ltd). Tritiated prostaglandins (3H-PG) were obtained from New England Nuclear and from the Radiochemical Centre, Amersham. Antiserum to PGE2 was obtained from May and Baker Ltd, by courtesy of Dr Whitnall; antiserum to PGF2: was supplied by Dr P Jose of the Pharmacology Department, Royal College of Surgeons; while antiserum to PGA1 was prepared in our own laboratories.
The assays were performed in disposable glass test tubes: 0.1 ml of sample was placed into each of three tubes, followed by 0.1 ml of 3H-PG containing about 4000 ct/min of radioactivity. Diluted antiserum 0.1 ml was added, and the solutions thoroughly mixed and stood overnight at 40C. In each assay, four tubes contained only buffer and another two sets of four tubes contained buffer instead of sample and antiserum respectively. In order to separate free from bound PG 0.2 ml of a solution of 5 mg/ml of bovine y-globulin (Cohn fraction II, Sigma) and 0.250 gelatin in buffer was added to each tube, followed by 0.5 ml of 250% polyethylene glycol 600 (BDH) in water, the mixture being maintained at 0°C in an ice bath. The tubes were mixed vigorously on a vortex mixer for 12 s and then centrifuged at 3000 g at 4°C for 30 min. The supernatants were decanted into plastic counting vials and mixed with 10 ml Instagel. The unbound PG was retained in the supernatant and its 3H content was counted in a Packard liquid scintillation counter.
In each assay a number of samples containing known quantities of the prostaglandin being assayed were included. A standard curve was obtained from these samples and the concentrations of prostaglandin in the unknowns calculated from this curve. Samples of unknown concentration were assayed at three dilutions. In this way, at least one, and usually two of the samples could be read from the standard curve.
Assay of Collagenase Activity
'4C-labelled collagen was prepared by injecting adult rats each with 50 1Ci of [U-_4C]/glycine (112 mCi/mmol) and [U-'4C]L-proline (290 mCi/ mmol) as a mixture subcutaneously at 74, 66, 50, 42 and 20 h before they were killed by cervical dislocation. The rats were then shaved and the skins removed, finely chopped and washed in frequent changes of large volumes of physiological saline for 3 days at 4°C. This procedure extracted the neutral salt-soluble collagen, which was discarded. The residue was washed three times with distilled water and then immersed in 0.5 M acetic acid and stirred gently at 4°C for 3 days to extract the acid-soluble collagen. This collagen was precipitated from solution by dialysis against three changes of a large volume of 5 % NaCl (w/v) in 0.1 M acetic acid. The collagen was precipitated, washed thoroughly with ice cold distilled water, freeze-dried and stored at -20°C. The specific activity was 10, 310 d/min per mg.
The assay for collagenase activity was based on that of Gisslow and McBride (1975) , excluding the acetylation step. The 14C-labelled collagen was dissolved in 0.01 % acetic acid to give a solution of 2 mg/ml by stirring overnight at 4°C. The reaction mixture consisted of 1 ml of collagen solution, 0.8 ml of 0.1 M tris-HCl buffer (pH 7.2) containing 0.01 M CaC12, and 0.2 ml of a solution of collagenase to be assayed. The assay tubes were incubated at 37°C for 24 hours, after which a 0.2ml aliquot was transferred to a Microfuge tube (Beckman) and 50 gl of 0.04 M phosphotungstic acid and 50 pl of 2 N HCI added. The tubes were kept at room temperature for 10 min, centrifuged for 5 min in a Beckman 152 Microfuge and the quantity of "4C in the supernatants counted in a Packard liquid scintillation counter. The activity of the enzyme could therefore be related directly to the percentage of radioactivity recovered in the supernatants.
Human Tissues Samples of benign and malignant lesions of the human breast removed at operation were received from the Pathology Department, Royal Marsden Hospital (London and Sutton, Surrey), in sterile tissue culture medium 199, usually at room temperature. Excess fat and connective tissue were immediately removed and the tissue carefully cut with large scalpels into slices 0.5-1 mm thick, and further trimmed to give areas of 2-3 mm2. A random selection of samples was then fixed in formol saline for subsequent histological examination and the remainder gently rinsed with Biggers' dissection medium before being placed on grids in the culture medium. At the end of the culture period the samples of tissue were gently blotted, quickly weighed, and some were fixed for subsequent histological examination, while others of known weight were kept for determination of DNA content.
Results
The ability of the bones in culture to respond to various amounts of known osteolytic agents, such as parathyroid hormone and prostaglandin E, was demonstrated first. The osteolytic activity of a series of primary breast carcinomas was then examined. Increases in calcium release which were less than 25 % above values obtained in the absence of any tissue were considered to be without significance, since most benign breast lesions and normal uninvolved skin and breast tissue gave this low degree of osteolytic activity. All the tumours examined were assessed histologically on the basis of tumour grade, degree of inflammatory infiltration, type and degree of stromal response and degree of necrosis before and after culture.
The only correlation between the boneresorbing activity of the cultured tumours and these parameters was that, in general, the more active tumours were associated with a more prominent stromal response and in particular with their histiocytic components. When the clinical status of the patients was examined, some correlation between osteolytic activity and the incidence of osteolytic bone metastases and hypercalcemia was apparent (Powles et al. 1976 ). Over a 3-year period all of 15 patients with osteolytically inactive tumours remained free of detectable bone metastases and hypercalcxemia, while of 23 patients with active tumours 7 either had or subsequently developed bone metastases, and 4 of these suffered from hypercalcemia (Table 1) . In order to eliminate the possibility that the increased release of 45Ca by bones in the presence of tumours was merely due to an increase in the rate of exchange of calcium between the culture medium and the bones, the bones were labelled in vivo with both 45Ca and 3H-proline, and the quantities of 45Ca and 3H released into the medium in the presence of four different breast tumours were examined. In each case there was good agreement between the percentages of 45Ca and 3H released from the bones, indicating that lysis of organic bone matrix as well as loss of calcium was taking place, and that true bone resorption was occurring.
We were impressed with a number of similarities to be seen in histological sections of bones undergoing resorption under the influence of tumour cells and in rheumatoid arthritis, and as aspirin and indomethacin were widely used for the treatment of rheumatoid arthritis the effects of these anti-inflammatory drugs on bone resorption in-duced by breast tumours in vitro was examined. Aspirin was used at concentrations of 1-16 jg/ml of culture medium and indomethacin at 0.1-1 gig/ml. In almost every case, the addition of these drugs to the media decreased the tumour-induced calcium release from the bones by approximately 80 %. If the tumours were cultured in medium alone and the medium was then transferred to bones, and aspirin or indomethacin were added at this stage, the reduction of osteolytic activity was much smaller (approximately 20 %), indicating that these drugs inhibited the synthesis or secretion of some of the osteolytic factors by the tumour tissues, and that once these factors had been released by the tumours they were only slightly inhibited by the drugs. As these nonsteroidal antiinflammatory agents are considered to act chiefly by inhibiting the synthesis of prostaglandins, it seemed probable that prostaglandins (some of which were known to possess in vitro osteolytic activity) were being synthesized by and released from the tumour tissue.
Prostaglandins, which are oxygenated cyclic fatty acids, can be extracted from aqueous solution with organic solvents such as ether following acidification of the aqueous phase to pH 3.5. When ether extracts of acidified media from breast tumour cultures were tested it was found that on average, about 50 % of the osteolytic activity could be extracted (Fig 1) . Control experiments demonstrated that the procedures used extracted 95-100 % of prostaglandins PGE1 and PGF2, present in aqueous solution. As indicated in Fig 1, of 15 tumours examined all the osteolytic activity originally present could be extracted from the medium of only one tumour, while no activity could be extracted from the media of two tumours, the remaining 12 yielding variable proportions of extractable activity. The prostaglandins present in these extracts were separated by thin-layer chromatography, extracted from the chromatograms, and the quantities measured by radioimmunoassay. The quantities of PGE1 and PGF2a,, two of the most potent osteolytic prostaglandins, corresponded well with the quantities known to be necessary to give the degree of osteolysis measured. It appeared therefore that release of PGE1 and PGF2a by the breast tumour fragments could account for approximately half of the observed in vitro osteolytic activity. Exhaustive dialysis of tumour culture media indicated that the remaining 500% of activity could not be removed from the media by this procedure, and that there was probably present a substance (or substances) of reasonably high molecular weight which made a significant contribution to the total osteolytic activity. Control experiments indicated that this nondialysable osteolytic activity could not be accounted for by the binding of prostaglandins to serum components present in the culture medium. The nature of these nondialysable osteolysins is at present unknown.
Dr Dowsett has recently performed experiments which indicate that some high molecular weight osteolytic agents may induce bone resorption in vitro by stimulating the synthesis of prostaglandins within the bone. He has observed that commercial preparations of bacterial collagenase can cause Table 3 Activity of collogenase in the prescence and abscence of aspirin and indomethacin (Table 2 ). If the cells in the bone are killed by repeated freeze-thawing, negligible loss of calcium occurs in the presence of collagenase, indicating that this enzyme can only bring about bone resorption with the active participation of living bone cells. The osteolytic effects were markedly inhibited both by inhibitors of prostaglandin synthetase and by the drug SC 19220 (Schering Chemicals Ltd), which inhibits the action of prostaglandins without inhibiting their synthesis. It was noted that although bone resorption by collagenase was largely abolished by these drugs the bones still collapsed, chiefly along the suture lines, and it was further demonstrated that these drugs, at the levels used, did not detectably inhibit the collagenolytic activity of the enzyme (Table 3) .
The equivalents of PGE2 present in the bone culture media in the presence and absence of collagenase, and in the presence and absence of indomethacin, were measured. Collagenase considerably increased the prostaglandin content of the medium, and this increase was reduced to control levels if indomethacin was also present (Table 4 ). These results indicate that preparations of collagenase could induce bone resorption by stimulating prostaglandin synthesis by cells associated with the bone. The loss of calcium from the bones can be inhibited by suppression of prostaglandin synthesis without loss of collagenase activity and without inhibiting degradation of collagen matrix along the suture lines.
We have recently found that some, but not all, breast fibroadenomas possess a significant degree of in vitro osteolytic activity. These tissues release considerable quantities of both prostaglandins and It cannot yet be excluded that these enzymes may constitute at least part of the nondialysable, osteolytically active, fraction which we have detected in many breast tumours and some fibroadenomas.
Finally, a note of warning. The application of tissue culture methods to the analysis of the factors and mechanisms involved in particular metabolic abnormalities associated with human cancers can be fruitful and stimulating, but they can also be very misleading, since they may oversimplify and distort the mechanisms which actually operate in patients. It is, therefore, essential to test any hypotheses derived from the application of tissue culture methods in suitable animal systems, and ultimately to establish their relationship to clinical studies. Breast cancer has a remarkable tendency to spread to and destroy bone. Osteolytic metastases and hypercalcoemia are both common complications of the disease (Galasko & Burns 1971) , and the mechanisms underlying osteolysis have recently been the subject of much research. Two factors have made meaningful research into the calcium metabolic patterns of patients with breast cancer extremely difficult to achieve. One is that the disease shows unpredictable variation in activity, and thus sudden phases of bone remodelling are interspersed with more prolonged periods of bone resorption. The other is that the patients are
